Literature DB >> 11107461

Lipid screening to prevent coronary artery disease: a quantitative evaluation of evolving guidelines.

S A Grover1, M Dorais, G Paradis, J G Fodor, J J Frohlich, R McPherson, L Coupal, H Zowall.   

Abstract

BACKGROUND: There is strong evidence to support the treatment of abnormal blood lipid levels among people with cardiovascular disease. Primary prevention is problematic because many individuals with lipid abnormalities may never actually develop cardiovascular disease. We evaluated the 1998 Canadian lipid guidelines to determine whether they accurately identify high-risk adults for primary prevention.
METHODS: Using data from the Lipid Research Clinics and receiver operating characteristic (ROC) curves, we compared the diagnostic performance of the 1998 lipid guidelines when risk factors for coronary artery disease (CAD) were counted versus calculating risk using Framingham risk equations. We also compared the diagnostic accuracy of the 1998 guidelines with guidelines previously published by the National Cholesterol Education Program in the United States and the 1988 Canadian Consensus Conference on Cholesterol and then used Canadian Heart Health Survey data to forecast lipid screening and treatment rates for the Canadian population.
RESULTS: The Framingham risk equations were more accurate than counting risk factors for predicting CAD risk (areas under the ROC curves, 0.83 [standard deviation (SD) 0.02] v. 0.77 [SD 0.03], p < 0.05). Risk counting was a particularly poor method for predicting risk for women. The 1998 Canadian guidelines identified high-risk individuals more accurately than the earlier guidelines, but the increased accuracy was largely due to a lower false-positive rate or a higher true-negative rate (i.e., increased test specificity). Using the 1998 lipid guidelines we estimate that 5.9 million Canadians currently free of cardiovascular disease would be eligible for lipid screening and 322,705 (5.5%) would require therapy.
INTERPRETATION: Calculating risk using risk equations is a more accurate method to identify people at high risk for CAD than counting the number of risk factors present, especially for women, and the 1998 Canadian lipid screening guidelines are significantly better at identifying high-risk patients than the 1988 guidelines. Many of our findings were incorporated into the new 2000 guidelines.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11107461      PMCID: PMC80320     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  27 in total

1.  An updated coronary risk profile. A statement for health professionals.

Authors:  K M Anderson; P W Wilson; P M Odell; W B Kannel
Journal:  Circulation       Date:  1991-01       Impact factor: 29.690

2.  Canadian heart health surveys: a profile of cardiovascular risk. Survey methods and data analysis. Canadian Heart Health Surveys Research Group.

Authors:  D R MacLean; A Petrasovits; M Nargundkar; P W Connelly; E MacLeod; A Edwards; P Hessel
Journal:  CMAJ       Date:  1992-06-01       Impact factor: 8.262

Review 3.  Canadian Consensus Conference on Cholesterol: final report. The Canadian Consensus Conference on the Prevention of Heart and Vascular Disease by Altering Serum Cholesterol and Lipoprotein Risk Factors.

Authors: 
Journal:  CMAJ       Date:  1988       Impact factor: 8.262

4.  Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events.

Authors:  S A Grover; L Coupal; S Paquet; H Zowall
Journal:  Arch Intern Med       Date:  1999-03-22

5.  A method of comparing the areas under receiver operating characteristic curves derived from the same cases.

Authors:  J A Hanley; B J McNeil
Journal:  Radiology       Date:  1983-09       Impact factor: 11.105

6.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.

Authors:  M H Frick; O Elo; K Haapa; O P Heinonen; P Heinsalmi; P Helo; J K Huttunen; P Kaitaniemi; P Koskinen; V Manninen
Journal:  N Engl J Med       Date:  1987-11-12       Impact factor: 91.245

7.  Plasma lipid distributions in selected North American populations: the Lipid Research Clinics Program Prevalence Study. The Lipid Research Clinics Program Epidemiology Committee.

Authors: 
Journal:  Circulation       Date:  1979-08       Impact factor: 29.690

8.  The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease.

Authors: 
Journal:  JAMA       Date:  1984-01-20       Impact factor: 56.272

9.  Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel.

Authors: 
Journal:  Arch Intern Med       Date:  1988-01

10.  Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study.

Authors:  W P Castelli; R J Garrison; P W Wilson; R D Abbott; S Kalousdian; W B Kannel
Journal:  JAMA       Date:  1986-11-28       Impact factor: 56.272

View more
  6 in total

1.  New heart risk equations do not affect existing guidelines.

Authors:  Richard Milne
Journal:  BMJ       Date:  2002-11-02

2.  Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease.

Authors:  Ruth McPherson; Jiri Frohlich; George Fodor; Jacques Genest
Journal:  Can J Cardiol       Date:  2006-09       Impact factor: 5.223

Review 3.  The role of global risk assessment in hypertension therapy.

Authors:  S A Grover; Brenda Hemmelgarn; Lawrence Joseph; Alain Milot; Guy Tremblay
Journal:  Can J Cardiol       Date:  2006-05-15       Impact factor: 5.223

4.  A comparison of Canadian and American guidelines for lipid management using data from the National Cholesterol Education Program Evaluation ProjecT Utilizing Novel E-technology (NEPTUNE) II survey.

Authors:  K C Maki; Michael H Davidson; Mary R Dicklin
Journal:  Can J Cardiol       Date:  2006-03-15       Impact factor: 5.223

5.  Statin use in Canadians: trends, determinants and persistence.

Authors:  C Ineke Neutel; Howard Morrison; Norm R C Campbell; Margaret de Groh
Journal:  Can J Public Health       Date:  2007 Sep-Oct

6.  Contribution of clinical risk factors to bone density-based absolute fracture risk assessment in postmenopausal women.

Authors:  W D Leslie; C Metge; L Ward
Journal:  Osteoporos Int       Date:  2003-04-25       Impact factor: 4.507

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.